Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit - 11/02/20
![](/templates/common/images/mail.png)
Funding sources: This study was supported by a grant from the Société Française de Dermatologie and an Investigator Initiated Trial from LEO Pharma. |
|
Conflicts of interest: Dr Passeron has received research grants and honoraria from LEO Pharma. Dr Lacour has received research grants from and has been a consultant for LEO Pharma. Dr Montaudié, Dr Duff, Dr Butori, Dr Hofman, Dr Fontas, Ms Roger-Cruzel, Dr Bahadoran, Dr Perrot, Dr Desmedt, and Dr Legoupil have no conflicts of interest to disclose. |
|
Disclaimer: Société Française de Dermatologie and LEO Pharma had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. |
|
Reprints not available from the authors. |
Vol 82 - N° 3
P. 731-733 - mars 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?